



**Supplemental Figure S5: Venetoclax enhances the efficacy of MRTX1133 in 2138 and 1245 tumors *in vivo*.** 2138 and 1245 KPC cells ( $2.5 \times 10^4$ ) were implanted via subcutaneous injection into the flanks of C57BL/6 mice. Once animals developed 250-300mm<sup>3</sup> tumors, they were treated with vehicle control (C, DMSO), Venetoclax (V, 15mg/kg daily), MRTX1133 (M, 30mg/kg 2x/day), or the combination of Venetoclax and MRTX1133. **A, B.** 2138 and 1245 tumors at the study endpoints were stained for pERK, BIM, the proliferation marker Ki-67, and the apoptosis marker cleaved caspase 3 (c-C3). Error bars  $\pm$  SD. One-way ANOVA, followed by Tukey's multiple comparison test. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ; ns, not significant.